Drugs / Rejuveinix
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03680105 | Aug 2018 → Jan 2019 | limb ischemia | Reven Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rejuveinix | “Rejuveinix (RJX) is an intravenous formulation of anti-oxidants and anti-inflammatory agents.” PMID 33244300 ↗ Nov 2020 |
| Known as | RJX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03680105 ↗ |
| Route | Intravenous | “RJX is an IV infusion formulation.” NCT03680105 ↗ |